Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes in Malaysia
doi.org/10.15605/jafes.038.01.12
- Author:
Mafauzy Mohamed
1
;
Siang Chin Lim
2
;
Malik Mumtaz
3
;
Shweta Uppal
4
;
Deepak Mukherjee
5
;
Mohamed Saiful Mohd Kassim
6
;
Shalini Sreedharan
7
;
Amudha Murugan Doraiswamy
8
;
Kuck Meng Chong
9
;
Lu Yu Tat
10
;
Sudzilla Binti Nordin
11
;
Jeshen Lau Hui Giek
12
;
Zanariah Hussein
13
;
Khalid Abdul Kadir
14
;
Bik Kui Lau
15
;
Siew Pheng Chan
16
Author Information
1. Universiti Sains Malaysia, Khota Bharu, Kelantan, Malaysia
2. Mahkota Medical Centre, Melaka, Malaysia
3. Island Hospital, Penang, Malaysia
4. NovoNordisk AS, Copenhagen, Denmark
5. NovoNordisk Pharma (Malaysia), Sdn Bhd, Kuala Lumpur Malaysia
6. Gleneagles Hospital, Kuala Lumpur, Malaysia
7. Pantai Hospital, Sugai Petani, Kedah, Malaysia
8. Pantai Hospital, Ayer Keroh, Melaka, Malaysia
9. Klinik Chong Slim River, Perak, Malaysia
10. Klinik Remedic, Perlis, Malaysia
11. Kota Bharu Medical Centre, Kota Bharu, Kelantan, Malaysia
12. Borneo Medical Centre, Kuching, Sarawak, Malaysia
13. Putrajaya Hospital, Putrajaya, Malaysia
14. Thomson Hospital, Kota Damansara, Selangor, Malaysia
15. KPJ Kuching Specialist Hospital, Malaysia
16. Subang Jaya Medical Centre (SJMC), Malaysia
- Publication Type:Journal Article
- From:
Journal of the ASEAN Federation of Endocrine Societies
2023;38(1):37-44
- CountryPhilippines
- Language:English
-
Abstract:
Objectives:Insulin degludec (IDeg)/insulin aspart (IAsp; IDegAsp) is a co-formulation of 70% IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective and safe for patients with type 2 diabetes mellitus (T2DM). A subgroup analysis of the ARISE study was conducted to explore the safety and efficacy of IDegAsp among Malaysian patients with T2DM in real-world settings.
Methodology:ARISE, an open-label, multicenter, non-interventional, prospective study was conducted between August 2019 and December 2020. Adult Malaysian patients with T2DM who were enrolled from 14 sites received IDegAsp as per the local label for 26 weeks. The primary endpoint was change in glycated hemoglobin (HbA1c) levels from baseline
to end of study (EOS).
Results:Of the 182 patients included in the full analysis set, 159 (87.4%) completed the study. From baseline to EOS, HbA1c (estimated difference [ED]: –1.3% [95% CI: –1.61 to –0.90]) and fasting plasma glucose levels (ED: –1.8 mmol/L [95% CI: –2.49 to –1.13]) were significantly reduced (p<0.0001). The patient-reported reduced hypoglycemic episodes (overall and nocturnal) during treatment. Overall, 37 adverse events were observed in 23 (12.6%) patients.
Conclusion:Switching or initiating IDegAsp treatment resulted in significant improvements in glycemic control and a reduction in hypoglycemic episodes.
- Full text:2461-Article Text-23115-1-10-20230516.pdf
